Journal
ONCOIMMUNOLOGY
Volume 11, Issue 1, Pages -Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/2162402X.2022.2093054
Keywords
Oncolytic virus; vascular normalization; tertiary lymphoid structure; STING; DC
Categories
Funding
- Fundamental Research Funds for the Central Universities [2019QNA7025]
- National Natural Science Foundation of China [81572800, 82073141, 81970004]
- Natural Science Foundation of Zhejiang Province [LR22H160006, LY15H160041]
Ask authors/readers for more resources
This study demonstrates that an oncolytic adenovirus carrying mIL-15 can induce an effective antitumor immune response and inhibit tumor growth in a mouse model of cancer. The virus promotes activation and infiltration of immune cells, as well as vascular normalization and tertiary lymphoid structure formation in the tumor microenvironment. These changes are dependent on the activation of the STING-TBK1-IRF3 pathway in dendritic cells.
Inducing a full antitumor immune response in the tumor microenvironment (TME) is essential for successful cancer immunotherapy. Here, we report that an oncolytic adenovirus carrying mIL-15 (Ad-IL15) can effectively induce antitumor immune response and inhibit tumor growth in a mouse model of cancer. We found that Ad-IL15 facilitated the activation and infiltration of immune cells, including dendritic cells (DCs), T cells and natural killer (NK) cells, in the TME. Unexpectedly, we observed that Ad-IL15 also induced vascular normalization and tertiary lymphoid structure formation in the TME. Moreover, we demonstrated these Ad-IL15-induced changes in the TME were depended on the Ad-IL15-induced activation of the STING-TBK1-IRF3 pathway in DCs. Taken together, our findings suggest that Ad-IL15 is a candidate for cancer immunotherapy that promotes immune cell activation and infiltration, tumor vascular normalization and tertiary lymphoid structure formation in the TME.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available